{"id":161531,"date":"2026-09-07T21:01:36","date_gmt":"2026-09-07T21:01:36","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/161531\/"},"modified":"2026-09-07T21:01:36","modified_gmt":"2026-09-07T21:01:36","slug":"novo-nordisk-says-semaglutide-cut-obesity-rates-in-young-children-in-trial-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/161531\/","title":{"rendered":"Novo Nordisk says semaglutide cut obesity rates in young children in trial"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">COPENHAGEN, Sept 7 (Reuters) &#8211; Novo Nordisk said on Monday that in a late-stage trial, 40.4% of \u200cchildren aged 6 to under 12 treated \u200cwith semaglutide, the active ingredient in its blockbuster weight-loss drug \u200bWegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">All patients enrolled in the trial, called STEP Young, received \u200clifestyle modification throughout \u2060the trial, including a reduced-calorie diet and increased physical activity, Novo said in a \u2060statement.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;We are encouraged by the positive STEP Young results and semaglutide&#8217;s potential to help children living with \u200bobesity \u200bwho need medical treatment, \u200balongside lifestyle changes, to \u200cbetter manage their obesity,&#8221; Novo&#8217;s Chief Scientific Officer Martin Holst Lange said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo said the trial met its primary endpoint demonstrating superior body mass index reduction at week 68 in the group taking once-weekly subcutaneous \u200csemaglutide compared with the placebo \u200bgroup.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The overall safety and tolerability \u200bof semaglutide were \u200bconsistent with those seen in trials with \u200cadults and adolescents, it added.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Prescriptions \u200bfor GLP-1 \u200bweight-loss drugs among U.S. children under 12 have risen more than 300-fold since 2019, a study \u200bpublished Friday \u200cfound, even though the drugs are not \u200bapproved for that age group.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by Louise Rasmussen, \u200bediting by Stine Jacobsen)  <\/p>\n","protected":false},"excerpt":{"rendered":"COPENHAGEN, Sept 7 (Reuters) &#8211; Novo Nordisk said on Monday that in a late-stage trial, 40.4% of \u200cchildren&hellip;\n","protected":false},"author":2,"featured_media":161532,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[75668,75667,108,35639,3845,272,4344,4512,27784],"class_list":["post-161531","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-40-4","tag-68-weeks","tag-copenhagen","tag-martin-holst-lange","tag-novo","tag-novo-nordisk","tag-reuters","tag-with","tag-young"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117231778998624641","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=161531"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161531\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/161532"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=161531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=161531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=161531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}